Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A

Long V. Dinh, PhD, Eli Fine, PhD, Afshin Ameri, MD, Bernadette W. Luu, B.S., M.T. (CLS), Satish Kumar, PhD, Vincent P. Diego, PhD, Joanne E. Curran, PhD, Juan M Peralta, M.S., Henry Mead, M.B.A., M.P.H., Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, John Blangero, PhD, Jerry S. Powell, MD, Timothy C. Nichols, MD, Robert P. Hebbel, MD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-142679

Published: 2020

Journal Articles

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Alexis Garza, B.S., Marco Hofmann, M.S., Marcio A. Almeida, PhD, Jerry S. Powell, MD, Long V. Dinh, PhD, Raja Rajalingam, PhD, Juan M Peralta, M.S., Satish Kumar, PhD, Eli Fine, PhD, Joanne E. Curran, PhD, Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142716

Published: 2020

Journal Articles

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Hari Movva, B.S., Marco Hofmann, M.S., Marcio A. Almeida, PhD, Long V. Dinh, PhD, Jerry S. Powell, MD, Raja Rajalingam, PhD, Juan M Peralta, M.S., Henry Mead, M.B.A., M.P.H., Satish Kumar, PhD, Joanne E. Curran, PhD, Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142493

Published: 2020

Journal Articles

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

Tom E. Howard, MD, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Marco Hofmann, M.S., Marcio A. Almeida, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, John Blangero, PhD, Maraskovsky Eugene, PhD, Vincent P. Diego, PhD

Blood (2019) 134 (Supplement_1): 161.

https://doi.org/10.1182/blood-2019-131727

Published: 2019

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

A Novel Biomarker for Inhibitor Risk Prediction-the HLA-II Bound and Unbound Components of FVIII Derived Peptides-Reveals a Protective Influence for N-Linked Glycosylation

Kevin R. Viel, PhD, Marco Hofmann, MD PhD, Sabine Zollner, Bernadette W. Luu, Rajalingam Raja, PhD, Jerry Sherman Powell, MD, Eugene Maraskovsky, MD, PhD, Tom E. Howard, MD PhD

Blood (2015) 126 (23): 2292.

https://doi.org/10.1182/blood.V126.23.2292.2292

Published: 2015

Journal Articles

The Spectrum of Amino Acid Substitutions Resulting from Single Nucleotide Substitutions in the Coagulation Biosystem: Impact on Identification By Mass Spectrometry

Kevin R. Viel, PhD, Benjamin Kim, MD MPhil, Maria Elizabeth Tejero, PhD, Shelley S. Cole, PhD, Tom E. Howard, MD PhD, Amparo Santamaría Ortiz, MD, PhD

Blood (2014) 124 (21): 4221.

https://doi.org/10.1182/blood.V124.21.4221.4221

Published: 2014

Journal Articles

Sequence-Modified Factor VIII Variants Having Reduced Immunogenicity

Ruth A. Ettinger, PhD, Melinda S. Epstein, PhD, Komal Puranik, MSc, Richard J. Hughes, PhD, Joseph A Liberman, BS, Eddie James, Ph.D., Tom E. Howard, MD, PhD, Shelley S. Cole, Ph.D., Dana C. Matthews, MD, Kathleen P. Pratt, PhD

Blood (2012) 120 (21): 39.

https://doi.org/10.1182/blood.V120.21.39.39

Published: 2012

Journal Articles

The Entire Primary Sequence of Factor VIII Is Synthesized As Two Polypeptide Chains in Hemophilia A Patients with the Intron-22-Inversion

Gouri Shankar Pandey, Ph.D, Susan Garfield, MS, Joanne E Curran, Ph.D, Eric K. Moses, Ph.D., Chava Kimchi-Sarfaty, Ph.D., Chen Yanover, PhD, Tom E. Howard, MD, PhD, Zuben E. Sauna, Ph.D.

Blood (2011) 118 (21): 1176.

https://doi.org/10.1182/blood.V118.21.1176.1176

Published: 2011

Journal Articles

Determination of Anti-Factor VIIII Antibody Titers, Isotypes and Epitopes by SPR Analysis of Human Plasma

Kenneth B Lewis, Ph.D., Phuong-Cac Nguyen, Ph.D., Jason T. Schuman, Ph.D., Christopher E. Walsh, MD, PhD, Neil C. Josephson, MD, Tom E. Howard, MD, PhD, Dana C. Matthews, MD, Nigel S. Key, MBChB, Kathleen P. Pratt, Ph.D.

Blood (2011) 118 (21): 202.

https://doi.org/10.1182/blood.V118.21.202.202

Published: 2011

Journal Articles

The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia A.

Tom E. Howard, MD, PhD, Shelley A. Cole, PhD, Carol K. Kasper, MD, Afshin Ameri, MD, Kavita Natarajan, MD, Raymond G. Watts, MD, Valrie A. Manard, RN, Shelley M. Nakaya, Christine L Kempton, MD, MSc, Martina Kennedy, DO, Benjamin Kim, MD, Rathi V. Iyer, MD, Laura Almasy, PhD

Blood (2009) 114 (22): 1301.

https://doi.org/10.1182/blood.V114.22.1301.1301

Published: 2009

Journal Articles

Potential Spectrum of Missense and Nonsense Factor (F)VIII Gene (F8) Alleles Based on Single Nucleotide Substitutions - How Many Remain To Be Identified?.

Kevin R. Viel, BS, Manana Khachidze, MD, PhD, MPH, Laura Almasy, PhD, Arthur R. Thompson, MD, PhD, Tom E. Howard, MD, PhD

Blood (2006) 108 (11): 4039.

https://doi.org/10.1182/blood.V108.11.4039.4039

Published: 2006

Journal Articles

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

Tom E. Howard, MD, PhD, Kevin R. Viel, BS, Karl M. Fernstrom, BS, Seema Deshpande, PhD, Afshin Ameri, MD, M. Showkat Ali, PhD, Cynthia Channell, BS, Rathi V. Iyer, MD, Raymond G. Watts, MD, Charles Lutcher, MD, Shelley Nakaya, BS, Carol K. Kasper, MD, Arthur R. Thompson, MD, PhD, Thomas C. Abshire, MD, Laura Almasy, PhD

Blood (2006) 108 (11): 765.

https://doi.org/10.1182/blood.V108.11.765.765

Published: 2006

Journal Articles

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

Tom E. Howard, MD, PhD, Deepa K. Machiah, BS, Kevin R. Viel, PhD, Cynthia Channel, BS, Afshin Ameri, MD, Rathi V. Iyer, MD, Ray G. Watts, MD, Charles Lutcher, MD, Joanna Davis, MD, Thomas C. Abshire, MD, Laura Almasy, PhD

Blood (2005) 106 (11): 3207.

https://doi.org/10.1182/blood.V106.11.3207.3207

Published: 2005

NARROW

Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

A Novel Biomarker for Inhibitor Risk Prediction-the HLA-II Bound and Unbound Components of FVIII Derived Peptides-Reveals a Protective Influence for N-Linked Glycosylation

The Spectrum of Amino Acid Substitutions Resulting from Single Nucleotide Substitutions in the Coagulation Biosystem: Impact on Identification By Mass Spectrometry

Sequence-Modified Factor VIII Variants Having Reduced Immunogenicity

The Entire Primary Sequence of Factor VIII Is Synthesized As Two Polypeptide Chains in Hemophilia A Patients with the Intron-22-Inversion

Determination of Anti-Factor VIIII Antibody Titers, Isotypes and Epitopes by SPR Analysis of Human Plasma

The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia A.

Potential Spectrum of Missense and Nonsense Factor (F)VIII Gene (F8) Alleles Based on Single Nucleotide Substitutions - How Many Remain To Be Identified?.

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only